Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷ : 2023-04-07
±³À°ÀÏÀÚ : 2023-04-07
±³À°Àå¼Ò : ¾Ú¹ö¼´õ ¼¿ï Ç®¸¸È£ÅÚ¿¡¼
±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í Àü°øÀÇ, °£È£»ç, ±âŸ 50000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 08:20~08:40 Real-world experience of emicizumab prophylaxis in young children with hemophilia in China: retrospective data from China Wanru Yao(Beijing Children)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 08:40~09:00 TSUBASA: A prospective study evaluating the association between physical activity and bleeding events in patients with hemophilia A without FVIII inhibitors during emicizumab prophylaxis Keiji Nogami(Nara Medical University, Japan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 09:00~09:20 Gene therapy for hemophilia in China Feng Xue(Institute of Haematology and Blood Diseases Hospital, China)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 09:20~09:40 Hemophilia A murine models with transduced human factor IX and X for applications of factor VIII mimicking bi-specific antibodies Sheng Chieh Chou(National Taiwan University Hospital, Taiwan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:05~10:25 Prothrombotic effect of emicizumab in an in vitro perfusion flow-chamber experiment using whole blood patients with von Willebrand disease Kenichi Ogiwara(Nara Medical University, Japan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:25~10:45 Managements of hemoperitoneum associated with ovulation in type 2 von Willebrand Disease: a single-institute experience in Taiwan Hsuan-Yu Lin(Changhua Christian Hospital, Taiwan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:45~11:05 Chinese guidelines on the diagnosis and management of von Willebrand disease Ziqiang YuJie Yin(The First Affiliated Hospital of Soochow University, China)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 11:05~11:25 Genetic confirmation of Glanzmann thrombasthenia and other inherited platelet function disorders in Korea Ye Jee Shim(Keimyung University Dongsan Hospital, Korea)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 11:35~12:10 Status of hemophilia A and B gene therapies in 2023 Glenn Pierce(World Federation of Hemophilia, Canada)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 12:10~12:50 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MG1113 in Healthy Subjects and Hemophilia Patients Jung Woo Han(Yonsei University Health System, Korea)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 13:00~13:40 Non-inversion variant in sporadic hemophilia A originate mainly in female: a result of variant-origin and timing study Ming-Ching Shen(Changhua Christian Hospital, Taiwan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 13:50~14:10 Therapeutic Outcomes of EHL Compared with SHL Clotting Factors in Patients with Severe Hemophilia in Taiwan Shyh-Shin Chiou(Kaohsiung Medical University Hospital, Taiwan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:10~14:30 Joint monitoring using musculoskeletal ultrasound in Japan Azusa Nagao(Ogikubo Hospital, Japan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:30~14:50 Novel classification system of hemophilic pseudotumor for surgical treatment Xisheng Weng(Peking Union Medical College Hospital, China)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:50~15:10 Perioperative replacement of factor concentrates for orthopedic surgery in hemophilia A patients with hemophilic arthropathy Jae Joon Han(Kyung Hee University, Korea)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:35~15:45 A Phase 3 Study to Evaluate Efficacy and Safety of Fitusiran in People with Hemophilia A or B who Switched Factor or Bypassing Agent Prophylaxis Chur-Woo You(Daejeon Eulji Medical Center, Korea)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:45~15:55 Patients¡¯ and parents¡¯ satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study Ji Yoon Kim(Kyungpook National University School of Medicine)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:55~16:05 Analysis of Antithrombin Levels and Thrombin Generation a Phase 3 Study of Fitusiran in People with Hemophilia A or B Without inhibitors Alok Srivastava(Christian Medical College, India)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 16:05~16:15 The Comparisons of Deep Learning Algorithms to Grade Hemophilic Arthropathy on X ray films Shao Li Han(Changhua Christian Hospital, Taiwan)
±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 16:15~16:25 Plasma long non-coding RNAs lncDC and THRIL as diagnostic markers of adult primary ITP Xin Li -> Nan Jiang(Qilu Hospital, China)